Quick answer
What do primary sources say about PT-141? As read on 17 November 2026: FDA's approval package records that bremelanotide was approved under NDA 210557 as the drug product Vyleesi on 21 June 2019.[1] FDA's 503A page lists the conditions a bulk drug substance must meet before a licensed pharmacist or physician may compound with it.[2] A Federal Register notice of 30 October 2026 announces a draft enforcement-discretion policy for compounding with certain peptide bulk substances; Appendix A of the linked policy lists six peptides and PT-141 is not among them.[3][5] The WADA 2026 Prohibited List does not name PT-141 or bremelanotide.[6] This article draws no legal conclusion and gives no legal advice. PT-141 from V8 is supplied for laboratory research use only.
Scope and ground rules
Searches for "legal considerations for buying PT-141" mix several different regulatory questions: whether the molecule is an approved drug, how pharmacies may compound with it, how research chemicals are labeled and sold, and what sport and employer rules say. Each question is governed by different documents. This article collects what the primary sources actually state about the first two, with dates, and says plainly what they leave open.
Ground rules: only primary sources are cited (FDA pages, the Federal Register notice, the HHS policy document and the WADA Prohibited List); statements are dated to the day they were read; no source is interpreted beyond its text; and nothing here is legal advice. Law-firm and news summaries were not used. Regulatory text changes, so a reader making a decision for an institution should read the current documents and consult its own compliance office or counsel.
| Question | Type of source that governs it | Covered in this article? |
|---|---|---|
| Is the molecule an approved drug ingredient? | FDA approval records | Yes[1] |
| What may licensed compounders use? | FDA 503A guidance and rulemaking | Yes[2][3] |
| How may a chemical be labeled and sold for lab work? | Other statutes, agency guidance, institutional policy | No |
| Sport rules | WADA Prohibited List | Yes[6] |
The compound in one paragraph
PT-141 (bremelanotide) is described in the V8 product listing (read 17 November 2026) as a melanocortin MC4 receptor agonist with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and the formula C50H68N14O10, which corresponds to a formula weight of about 1,025 Da. A 2006 review (Hadley and Dorr) describes PT-141 as a new analog of melanotan II within the family of melanocortin peptide analogs.[4] The listing gives a 10 mg size, ≥98% HPLC purity, lyophilized powder in a sealed clear glass vial, and storage at 2-8 °C with −20 °C for long-term. Science and handling are covered in the PT-141 research overview and PT-141 vs melanotan II.
Document 1: the FDA approval record (2019)
FDA's approval package for NDA 210557 identifies the product as Vyleesi (bremelanotide) in a subcutaneous presentation, names AMAG Pharmaceuticals as the sponsor and gives the approval date as 21 June 2019.[1] The practical meaning for a molecule-level discussion is narrow and factual: bremelanotide is the active ingredient of an FDA-approved drug product. It is a statement about that product and its sponsor's application. It is not a statement about whether other materials containing the same peptide are, or are not, permitted for any other purpose, and the approval package does not address research-use-only chemicals.
Document 2: FDA on bulk drug substances in 503A compounding
FDA's page on section 503A of the FD&C Act, read on 17 November 2026, states that state-licensed physicians and pharmacists may only compound drug products using bulk drug substances that (1) comply with an applicable USP or NF monograph where one exists, (2) are components of FDA-approved drug products where no monograph exists, or (3) appear on FDA's 503A bulks list where neither applies.[2] It adds that bulk substances must be accompanied by a valid certificate of analysis and manufactured by an establishment registered with FDA, and it urges compounders to know their bulks supplier.[2] The page also describes the rulemaking history: a final regulation in February 2019 that placed six substances on the list and did not place four others, and a proposed regulation in September 2019 on further amendments.[2]
Document 3: the 30 October 2026 Federal Register notice
On 30 October 2026 the Department of Health and Human Services published a notice of availability (91 FR 68526, document 2026-22192, docket HHS-OASH-2026-0496) announcing a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances."[3] According to the notice, the policy describes how HHS intends to approach the use of certain peptide bulk drug substances in 503A compounding while the 503A bulks list is developed through rulemaking, and HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with a peptide bulk substance found in the policy's Appendix A. The notice says the policy is a draft, does not establish rights for any person and is not binding, and that HHS may revisit it, for example if a safety signal or product-quality issue arises. Written comments were invited for two weeks after publication.[3]
The notice text does not itself list the peptides. Appendix A of the policy document it links, read on 17 November 2026, is titled "List of Peptide Bulk Drug Substances Addressed by HHS Interim Enforcement Policy Regarding 503A Compounding" and lists six substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. PT-141 and bremelanotide are not among them.[5] The policy document also states the Secretary's determination that the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk" (the sentence continues beyond this quotation). It is quoted as worded; this article does not interpret it, and the Federal Register notice itself does not mention research-use-only materials.
Document 4: the WADA 2026 Prohibited List
The 2026 Prohibited List states that it "shall come into effect on 1 January 2026." The English PDF on wada-ama.org was read on 17 November 2026, including its alphabetical index. The terms bremelanotide, PT-141 and melanotan do not appear in it.[6] "Not named" describes that text only; it is not a statement about any other WADA document or rule.
Source-by-source summary
| Source | Date | What it states | What it does not state |
|---|---|---|---|
| FDA approval package, NDA 210557[1] | Approval 21 June 2019 | Bremelanotide is the active ingredient of an FDA-approved drug product, Vyleesi; sponsor AMAG Pharmaceuticals, Inc | Anything about research-use-only materials or other uses |
| FDA 503A bulk drug substances page[2] | Read 17 Nov 2026 | Three routes by which a bulk substance may be used by licensed compounders; certificate-of-analysis and registered-establishment conditions | Whether a particular peptide qualifies |
| Federal Register notice 2026-22192[3] | Published 30 Oct 2026 | A draft enforcement-discretion policy for 503A compounding with certain peptide bulk substances; draft, non-binding, comments invited | The list of peptides (in the linked policy) |
| HHS policy document, Appendix A[5] | Read 17 Nov 2026 | Six listed peptides: BPC-157, epitalon, KPV, MOTS-c, semax, TB-500 | Any entry for PT-141 or bremelanotide |
| WADA 2026 Prohibited List[6] | In force 1 Jan 2026 | Does not name PT-141, bremelanotide or melanotan | Anything about substances it does not name |
| Review of melanocortin peptide analogs[4] | 2006 | Historical context for melanotan analogs and PT-141 | Current regulatory status |
What these sources do not cover
The FDA approval package and the 503A page concern drug products or the compounding of drug products by licensed professionals. Neither is about how a chemical supplier may label and sell a material for in vitro or non-clinical laboratory work, and neither mentions research-use-only materials. The HHS policy document contains the single research-use-only sentence quoted above. Other subjects, including state law, customs, institutional rules and workplace rules, are outside the documents read here. A reader who needs an answer on any of these points should consult the relevant primary source or qualified counsel; a summary on a supplier's website is not a substitute.
For the general picture of how research peptides are positioned, see research peptide legal status in the US, and for supplier documentation expectations see vetting a research peptide supplier.
Research-use statement
PT-141 sold by V8 is labeled for laboratory research use only; not for human or animal consumption. Documents summarized above are quoted or paraphrased from the cited primary sources as read on 17 November 2026; they may have changed since. For how to read lot documentation, see how to read a COA, the COA page and the reconstitution calculator. Browse other materials in the shop.
Related reading
- PT-141 research overview: the pillar guide
- PT-141 product page: size, purity and storage line
- Research peptide legal status in the US
- Where to buy PT-141: documentation to expect
- PT-141 vs melanotan II: research comparison
- Vetting a research peptide supplier
- How to read a COA
- Browse all research compounds
Frequently asked questions
Is bremelanotide an FDA-approved drug ingredient?
FDA's approval package records Vyleesi (bremelanotide) under NDA 210557 with an approval date of 21 June 2019.[1] That is a statement about that drug product.
Does FDA's 503A page mention PT-141?
The page text read for this article describes the conditions for compounding bulk substances in general and does not discuss PT-141 individually.[2]
What did the 30 October 2026 Federal Register notice announce?
A draft enforcement-discretion policy for 503A compounding with certain peptide bulk drug substances, pending development of the 503A bulks list through rulemaking. It is described as a draft that is not binding.[3]
Is PT-141 on the policy's Appendix A list?
No. As read on 17 November 2026, Appendix A lists BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.[5]
Does the WADA 2026 List name PT-141?
The English 2026 Prohibited List text read on 17 November 2026 does not contain PT-141, bremelanotide or melanotan.[6]
Do these documents say anything about research-use-only chemicals?
The approval package, the 503A page and the Federal Register notice do not. The HHS policy document has one sentence about research-use-only peptides supplied by foreign manufacturers, quoted in this article without interpretation.
Can this article be used as legal advice?
No. It is a dated, neutral summary of primary-source text. Institutions should consult their compliance office or counsel.
Why do some pages say "check the date"?
Regulatory documents can be amended or replaced. Every statement here is tied to the date the source was read, 17 November 2026.
What does the PT-141 product page list?
A 10 mg size, ≥98% HPLC purity, formula C50H68N14O10, lyophilized powder in a sealed clear glass vial, stored at 2-8 °C with −20 °C for long-term.
Is V8 PT-141 for people or animals?
No. It is labeled for laboratory research use only; not for human or animal consumption.
Related reading: Research Peptide Documents in 2026: HHS, FDA and WADA Read, Tirzepatide: FDA, HHS and WADA Documents Read, BPC-157 Regulatory Documents in 2026: A Dated Reading, BPC-157 and TB-500: US Regulatory Documents in 2026.
References
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Approval Package, NDA 210557, Vyleesi (bremelanotide); approval date 06/21/2019. accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000Approv.pdf (read 17 November 2026).
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act (page read 17 November 2026).
- Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register. 2026 Oct 30;91(209):68526-68527. Document 2026-22192. https://www.federalregister.gov/documents/2026/10/30/2026-22192 (read 17 November 2026).
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029 PMID: 16412534
- Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy document, Appendix A). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf (read 17 November 2026).
- World Anti-Doping Agency. The 2026 Prohibited List, World Anti-Doping Code International Standard. In force 1 January 2026. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (text read 17 November 2026).
